Avicenna Biosciences Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$5.98M
- Investors
-
2
Avicenna Biosciences General Information
Description
Developer of an ML-driven medicinal chemistry platform intended to redesign and optimize drug candidates. The company utilizes ensemble-based machine learning approaches to identify new chemical entities and expand the range of challenges that can be overcome, and transform sub-optimal development candidates into life-saving drugs, and make lead optimization faster and cheaper, enabling pharmaceutical companies to reduce any deficiencies in their drugs.
Contact Information
Website
www.avicenna-bio.comCorporate Office
- 101 West Chapel Hill Street
- Suite 210
- Durham, NC 27701
- United States
Corporate Office
- 101 West Chapel Hill Street
- Suite 210
- Durham, NC 27701
- United States
Avicenna Biosciences Timeline
Avicenna Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 28-Oct-2025 | $5.98M | Completed | Generating Revenue | ||
| 3. Debt - General | 16-Jul-2024 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 23-Feb-2024 | $6M | $8.5M | Completed | Generating Revenue | |
| 1. Seed Round | 14-Sep-2020 | $2.5M | $2.5M | Completed | Generating Revenue |
Avicenna Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Avicenna Biosciences Patents
Avicenna Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026011129-A1 | Azaindole rock inhibitors for the treatment of medical disorders | Pending | 03-Jul-2024 | ||
| WO-2026011126-A1 | Azaindole rock inhibitors with advantageous properties | Pending | 03-Jul-2024 | ||
| WO-2026011127-A1 | New rock inhibitors | Pending | 03-Jul-2024 | ||
| AU-2023415105-A1 | Azaindole rock inhibitors | Pending | 30-Dec-2022 | ||
| EP-4642764-A2 | Azaindole rock inhibitors | Pending | 30-Dec-2022 | C07D471/04 |
Avicenna Biosciences Signals
Avicenna Biosciences Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| DCVC Bio | Venture Capital | Minority | ||
| DCVC | Venture Capital | Minority |
Avicenna Biosciences FAQs
-
When was Avicenna Biosciences founded?
Avicenna Biosciences was founded in 2020.
-
Where is Avicenna Biosciences headquartered?
Avicenna Biosciences is headquartered in Durham, NC.
-
What is the size of Avicenna Biosciences?
Avicenna Biosciences has 12 total employees.
-
What industry is Avicenna Biosciences in?
Avicenna Biosciences’s primary industry is Biotechnology.
-
Is Avicenna Biosciences a private or public company?
Avicenna Biosciences is a Private company.
-
What is Avicenna Biosciences’s current revenue?
The current revenue for Avicenna Biosciences is .
-
How much funding has Avicenna Biosciences raised over time?
Avicenna Biosciences has raised $20.5M.
-
Who are Avicenna Biosciences’s investors?
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process